Treatment of Dupuytren's disease using one full dose of Clostridium histolyticum collagenase at a lower concentration: Retrospective analysis of clinical outcomes

2020 ◽  
Vol 39 (4) ◽  
pp. 316-319
Author(s):  
Y. Goubau ◽  
B. Vanmierlo ◽  
C.-K. Goorens ◽  
J.F. Goubau
2020 ◽  
Vol 45 (5) ◽  
pp. 508-512
Author(s):  
Rafael Sanjuan-Cervero ◽  
Francisco J. Carrera-Hueso ◽  
Manuel Vaquero-Perez ◽  
Daniel Montaner-Alonso

The aim of this study was to determine whether recurrent Dupuytren’s disease after collagenase Clostridium histolyticum treatment differs histologically from recurrence in those treated with fasciectomy. We carried out a prospective cohort study of patients with Dupuytren’s disease who underwent fasciectomy to treat disease recurrence after previous treatment with collagenase Clostridium histolyticum or fasciectomy. The pathologists and statistician were blinded to the previous treatment. Longitudinal biopsy sections were stained with haematoxylin-eosin and the nodular zones were examined. Fifteen patients were studied: nine previously treated with collagenase Clostridium histolyticum and six previously treated with fasciectomy. There were no histological differences between the samples from the two groups of patients. Dupuytren’s disease recurrences after fasciectomy and collagenase Clostridium histolyticum are histologically indistinguishable.


Author(s):  
M.Á. Martín-Ferrero ◽  
C. Simón-Pérez ◽  
J.I. Rodríguez-Mateos ◽  
B. García-Medrano ◽  
R. Hernández-Ramajo ◽  
...  

2010 ◽  
Vol 35 (12) ◽  
pp. 2027-2038.e1 ◽  
Author(s):  
David Gilpin ◽  
Stephen Coleman ◽  
Stephen Hall ◽  
Anthony Houston ◽  
Jeff Karrasch ◽  
...  

Hand ◽  
2013 ◽  
Vol 8 (3) ◽  
pp. 261-266 ◽  
Author(s):  
Heather A. McMahon ◽  
Abdo Bachoura ◽  
Sidney M. Jacoby ◽  
David S. Zelouf ◽  
Randall W. Culp ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document